{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:32:19Z","timestamp":1768516339159,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Activated clotting time (ACT)-based heparin dosing during percutaneous intervention (PCI) is recommended by Society guidelines. However, the relationship between ACT and outcome in the setting of elective PCI has not been sufficiently studied. We sought to evaluate the in-hospital outcome of patients undergoing elective PCI while receiving fixed-dose heparin without ACT measurement versus those with ACT-guided management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included consecutive patients undergoing elective PCI in a single-center between 11\/2015 and 12\/2018. Patients were divided into two groups, depending on whether ACT was measured. Heparin-only anticoagulation and non-femoral procedures were allowed. Patient demographics, procedural data and in-hospital outcomes were collected. The primary outcome was in-hospital major adverse cardiovascular events (MACE), secondary (safety) outcomes were in-hospital definite stent thrombosis, Bleeding Academic Research Consortium bleeding, access-related complications (any) as well as peri-procedural complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 500 procedures were included in the study, 151 ACT and 349 fixed-dose. Patient demographics and medical history in both groups were well balanced, but those having ACTs were younger (63.2\u2009\u00b1\u200910.9 vs. 66.5\u2009\u00b1\u200911.3; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.003) and less likely to have a history of coronary artery disease (74 vs. 82%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.032) or kidney failure. Procedural data were similar; however, total heparin dose and procedure length were higher in the ACT group (6232\u2009\u00b1\u20091388 vs.5032\u2009\u00b1\u2009417 units; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001; 40.1\u2009\u00b1\u200914.0 vs. 30.3\u2009\u00b1\u200912.7\u2009min; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). Primary and secondary outcome events were rare and similar (MACE 1.1 vs. 1.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.86).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A fixed-dose heparin injection (5000 IU) approach for elective PCI while omitting ACT offers slightly shortened procedural time and similar in-hospital safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001008","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T22:01:15Z","timestamp":1611093675000},"page":"549-553","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Routine fixed-dose heparin vs. ACT-guided heparin administration for elective PCI and its influence on patient in-hospital outcome: a retrospective study"],"prefix":"10.1097","volume":"32","author":[{"given":"Oron","family":"Berkowitz","sequence":"first","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar Ilan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majdi","family":"Halabi","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar Ilan University"},{"name":"Division of Cardiology, Ziv Medical Center, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar Ilan University"},{"name":"Division of Cardiology, Ziv Medical Center, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar Ilan University"},{"name":"Division of Cardiology, Ziv Medical Center, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Sharabi-Nov","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ziv Medical Center, Safed"},{"name":"Tel-Hai College, Upper Galilee, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zippi","family":"Regev-Avraham","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ziv Medical Center, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeev","family":"Israeli","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar Ilan University"},{"name":"Division of Cardiology, Ziv Medical Center, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/heart.88.4.331","article-title":"Heparin dose during percutaneous coronary intervention: how low dare we go?","volume":"88","author":"Niccoli","year":"2002","journal-title":"Heart"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.amjcard.2009.10.043","article-title":"Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention.","volume":"105","author":"Shimada","year":"2010","journal-title":"Am J Cardiol"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9149(03)00637-4","article-title":"Relation between the degree of procedural anticoagulation and complications after coronary stent implantation.","volume":"92","author":"Ashby","year":"2003","journal-title":"Am J Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCINTERVENTIONS.111.961912","article-title":"Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.","volume":"4","author":"Bangalore","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention aggregate: results from 6 randomized, controlled trials.","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.thromres.2016.04.025","article-title":"The effect of activated clotting time values for patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.","volume":"144","author":"Gui","year":"2016","journal-title":"Thromb Res"},{"key":"R9-20250729","first-page":"351","article-title":"Defining optimal activated clotting time for percutaneous coronary intervention: a systematic review and Bayesian meta-regression.","volume":"89","author":"Mottillo","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018).","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(02)02767-5","article-title":"Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.","volume":"41","author":"Tolleson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jacc.2008.07.026","article-title":"The CIAO (coronary interventions antiplatelet-based only) study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention.","volume":"52","author":"Stabile","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/joic.12081","article-title":"Low-dose heparin for elective percutaneous coronary intervention.","volume":"27","author":"Lee","year":"2014","journal-title":"J Interv Cardiol"},{"key":"R15-20250729","first-page":"984","article-title":"[Efficacy and safety of low-dose heparin (30 IU\/kg) during coronary angioplasty].","volume":"94","author":"Godon","year":"2001","journal-title":"Arch Mal Coeur Vaiss"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/hrt.77.6.517","article-title":"Safety of low dose heparin in elective coronary angioplasty.","volume":"77","author":"Koch","year":"1997","journal-title":"Heart"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0002-9149(99)00908-X","article-title":"Minimal heparinization in coronary angioplasty\u2013how much heparin is really warranted?","volume":"85","author":"Kaluski","year":"2000","journal-title":"Am J Cardiol"},{"key":"R18-20250729","first-page":"408","article-title":"[Activated clotting time post therapeutic anticoagulation with unfractionated heparin in patients undergoing elective percutaneous coronary intervention].","volume":"43","author":"Li","year":"2015","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.amjcard.2015.12.003","article-title":"Relation of activated clotting times during percutaneous coronary intervention to outcomes.","volume":"117","author":"Rajpurohit","year":"2016","journal-title":"Am J Cardiol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:08:12Z","timestamp":1753812492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001008","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}